GRFS

Grifols, S.A. (NASDAQ:GRFS) is a Spanish multinational pharmaceutical and chemical company founded in 1940 and headquartered in Barcelona, Spain. The company went public on NASDAQ in 2011 and has grown to become one of the world's largest producers of plasma-derived medicines. Grifols operates through multiple divisions including Bioscience, Hospital, Diagnostic, and Bio Supplies, serving healthcare providers globally with products used to treat chronic, rare, and life-threatening diseases. The company has undergone significant operational restructuring in recent years, including leadership changes with Nacho Abia becoming CEO in 2024, as it works to improve financial performance and reduce leverage following a period of rapid expansion.